Skip to main content

Table 2 Median adherence percentage with inter-quartile range at each study visit, by adherence measure

From: Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?

  n Week 16 n Week 48
Self-report (%): median (IQR) 140 100 (100–100) 169 100 (100–100)
Pill count (%): median (IQR) 160 100 (92–100) 178 100 (95–107)
Average pharmacy refill (%): median (IQR)a 158 104 (101–105) 178 103 (95–105)
Gaps pharmacy refill (%): median(IQR)a 158 100 (100–100) 178 100 (95–100)
EAMD adherence (%): median (IQR)a 160 93 (74–98) 180 86 (59–94)
EFV concentration (mg/L): median(IQR) 136 2.3 (1.6–4.4) 156 2.1 (1.5–3.4)
Viral suppression: n (%) 160 146 (91.2) 180 153 (85.0)
  1. Self-report and EFV concentrations are measured on the date of the visit. Tablet counts cover the 30 days (week 16) or 60 days (week 48) before the visit. Pharmacy refill and EAMD adherence are cumulative data from baseline to latest time in care
  2. aCumulative per protocol measures